microRNA-128-3p inhibits CD4+ regulatory T cells enrichment by targeting interleukin 16 in gastric cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635–648.
   PubMed Web of Science ®Google Scholar
• Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551–564.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–1725.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889–1894.
   PubMed Web of Science ®Google Scholar
• Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117(4):451–460.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109–118.
   PubMed Web of Science ®Google Scholar
• Wilczynski JR. The role of T-regulatory cells in pregnancy and cancer. Front Biosci. 2008;13(13):2275–2289.
   PubMedGoogle Scholar
• Lee HM, Nguyen DT, Lu LF. Progress and challenge of microRNA research in immunity. Front Genet. 2014;5:178.
   PubMed Web of Science ®Google Scholar
• Paladini L, Fabris L, Bottai G, et al. Targeting microRNAs as key modulators of tumor immune response. J Exp Clin Cancer Res. 2016;35(1):103.
   PubMedGoogle Scholar
• Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651–658.
   PubMed Web of Science ®Google Scholar
• Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–5912.
   PubMed Web of Science ®Google Scholar
• Wang X, Xin S, Wang Y, et al. MicroRNA-146a-5p enhances T helper 17 cell differentiation via decreasing a disintegrin and metalloprotease 17 level in primary sjögren’s syndrome. Bioengineered. 2021;112(1):310–324.
   Google Scholar
• Yin Y, Cai X, Chen X, et al. Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth. Cell Res. 2014;24(10):1164–1180.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lei J, Fang ZL, et al. MiR-128b is down-regulated in gastric cancer and negatively regulates tumour cell viability by targeting PDK1/Akt/NF-kappaB axis. J Biosci. 2016;41(1):77–85.
   PubMed Web of Science ®Google Scholar
• Xu X, Lu X, Dong X, et al. Effects of hMASP-2 on the formation of BCG infection-induced granuloma in the lungs of BALB/c mice. Sci Rep. 2017;7(1):2300.
   PubMedGoogle Scholar
• Wu Y, Yuan MH, Wu HT, et al. MicroRNA-488 inhibits proliferation and motility of tumor cells via downregulating FSCN1, modulated by Notch3 in breast carcinomas. Cell Death Dis. 2020;11(10):912.
   PubMed Web of Science ®Google Scholar
• Ni H, Qin H, Sun C, et al. MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res Ther. 2021;12(1):325.
   PubMed Web of Science ®Google Scholar
• Xu X, Ban Y, Zhao Z, et al. MicroRNA-1298-3p inhibits proliferation and invasion of glioma cells by downregulating Nidogen-1. Aging (Albany NY). 2020;12(9):7761–7773.
   PubMedGoogle Scholar
• Shibuya N, Kakeji Y, Shimono Y. MicroRNA-93 targets WASF3 and functions as a metastasis suppressor in breast cancer. Cancer Sci. 2020;111(6):2093–2103.
   PubMed Web of Science ®Google Scholar
• Jaime-Ramirez AC, Yu JG, Caserta E, et al. Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. Mol Ther Oncolytics. 2017;10(5):87–96.
   Google Scholar
• Xi Q, Chen Y, Yang GZ, et al. miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer. Front Immunol. 2020;11:890.
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
   PubMed Web of Science ®Google Scholar
• Gao M, Yu T, Liu D, et al. Sepsis plasma-derived exosomal miR-1-3p induces endothelial cell dysfunction by targeting SERP1. Clin Sci (Lond). 2021;135(2):347–365.
   PubMed Web of Science ®Google Scholar
• Huang Y, Du KL, Guo PY, et al. IL-16 regulates macrophage polarization as a target gene of mir-145-3p. Mol Immunol. 2019;107:1–9.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang S, Li X, et al. Vaccination with a co-expression DNA plasmid containing GAD65 fragment gene and IL-10 gene induces regulatory CD4(+) T cells that prevent experimental autoimmune diabetes. Diabetes Metab Res Rev. 2016;32(6):522–533.
   PubMed Web of Science ®Google Scholar
• Sharpe H. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol Rev. 2017;276(1):5–8.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287.
   PubMed Web of Science ®Google Scholar
• Cioffi M, Trabuco SM, Vallespinos M, et al. The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget. 2017;8(13):21609–21625.
   PubMedGoogle Scholar
• Mari L, Hoefnagel SJM, Zito D, et al. microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. Gastroenterology. 2018;155(3):784–798.
   PubMed Web of Science ®Google Scholar
• Wang P, Guo X, Zong W, et al. MicroRNA-128b suppresses tumor growth and promotes apoptosis by targeting A2bR in gastric cancer. Biochem Biophys Res Commun. 2015;467(4):798–804.
   PubMed Web of Science ®Google Scholar
• Wang P, Guo X, Zong W, et al. PGC-1alpha/SNAI1 axis regulates tumor growth and metastasis by targeting miR-128b in gastric cancer. J Cell Physiol. 2019;234(10):17232–17241.
   PubMed Web of Science ®Google Scholar
• Liang X, Shangguan W, Zhang M, et al. miR-128 enhances dendritic cell-mediated antitumor immunity via targeting of p38. Mol Med Rep. 2017;16(2):1307–1313.
   PubMed Web of Science ®Google Scholar
• Yuan L, Xu B, Yuan P, et al. Tumor-infiltrating CD4+ T cells in patients with gastric cancer. Cancer Cell Int. 2017;17(1):114.
   PubMedGoogle Scholar
• Choi HS, Ha SY, Kim HM, et al. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget. 2016;7(7):7940–7951.
   PubMedGoogle Scholar
• Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 2003;9(12):4404–4408.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang Y, Tan W, et al. Silencing of long non-coding RNA NEAT1 improves Treg/Th17 imbalance in preeclampsia via the miR-485-5p/AIM2 axis. Bioengineered. 2021;12(1):8768–8777.
   PubMed Web of Science ®Google Scholar
• Wieckowski EU, Visus C, Szajnik M, et al. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009;183(6):3720–3730.
   PubMed Web of Science ®Google Scholar
• Kato T, Noma K, Ohara T, et al. Cancer-Associated Fibroblasts Affect Intratumoral CD8(+) and FoxP3(+) T Cells Via IL6 in the Tumor Microenvironment. Clin Cancer Res. 2018;24(19):4820–4833.
   PubMed Web of Science ®Google Scholar
• Moore A, Huang WY, Danforth K, et al. Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2018;29(4–5):455–464.
   PubMed Web of Science ®Google Scholar
• Comperat E, Roupret M, Drouin SJ, et al. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate. 2010;70(15):1622–1627.
   PubMed Web of Science ®Google Scholar
• Gao LB, Rao L, Wang YY, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis. 2009;30(2):295–299.
   PubMed Web of Science ®Google Scholar
• Yang H, Han Y, Wu L, et al. Diagnostic and prognostic value of serum interleukin16 in patients with gastric cancer. Mol Med Rep. 2017;16(6):9143–9148.
   PubMed Web of Science ®Google Scholar
• Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000;67(6):757–766.
   PubMed Web of Science ®Google Scholar
• Lynch EA, Heijens CA, Horst NF, et al. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol. 2003;171(10):4965–4968.
   PubMed Web of Science ®Google Scholar
• McFadden C, Morgan R, Rahangdale S, et al. Preferential migration of T regulatory cells induced by IL-16. J Immunol. 2007;179(10):6439–6445.
   PubMed Web of Science ®Google Scholar